{
    "nct_id": "NCT03873883",
    "official_title": "Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers",
    "inclusion_criteria": "* Women and men â‰¥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Subject with histologically or cytologically confirmed advanced solid tumor for whom no standard treatment is further available.\n* At least 4 weeks since any previous treatment for cancer\n* Subject must consent to pretreatment and on treatment tumor biopsies\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted\n* Participants with second/other active cancers requiring current treatment\n* Uncontrolled/significant heart disease\n* Known History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)\n* Active/uncontrolled autoimmune disease\n* Active infection\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding participation in the Trial, please refer to your physician"
}